Monte Rosa Therapeutics Inc Stock price
Compare with Peer Group
📊 Peer Group
📈 What is it?
The peer group consists of the companies with the most similar business model. They serve as a benchmark for putting a stock into context.
🧮 How is it selected?
Based on similarity of business model, meaning companies from the same industry with comparable products and a similar customer base. That's the only way to compare apples to apples.
🏛️ Why does it matter?
Whether a stock is cheap or expensive is best judged by comparison. A P/E of 18 or an EV/FCF of 20 can look cheap or expensive depending on the yardstick. The peer group gives you the most accurate one: companies with a similar business model that operate under the same conditions.
🎯 What does it mean for investors?
When a metric sits below the peer average, the stock is valued more cheaply relative to its competitors, and above the average more expensively. A discount to the peer group can be an opportunity, but it can also have a reason (for example lower growth). The comparison is a starting point, not a verdict.
Is Monte Rosa Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.
StocksGuide Premium
StocksGuide Unlimited
Key metrics
📘 Market Capitalization
📈 What is it?
Market capitalization shows how much a company is currently worth on the stock market.
🧮 How is it calculated?
🏛️ Why is it important?
It helps classify companies by size (Large, Mid, Small Cap) and indicates their market presence and relative stability.
🧮 Calculation
🎯 What does this mean for investors?
- Large-cap companies tend to be more stable, often pay dividends, but may grow more slowly.
- Smaller firms may offer higher growth potential but come with more volatility.
- Market capitalization is a useful indicator of company size — but not a measure of whether a stock is undervalued or overvalued.
📘 Enterprise Value (EV)
📈 What is it?
Enterprise Value represents the total cost to acquire a company — including its debt and excluding its cash reserves.
🧮 How is it calculated?
(= Market Cap + Net Debt)
🏛️ Why is it important?
EV gives a more complete picture of a company's value than market cap alone and is used in key valuation ratios like EV/FCF or EV/Sales.
🧮 Calculation
🎯 What does this mean for investors?
- Enterprise Value shows the true cost of buying a company, including all financial obligations.
- It is more accurate than just looking at market cap, especially when comparing companies with different levels of debt or cash.
- Professional investors prefer EV-based multiples because they better reflect the company’s full financial footprint.
📘 Net Debt
📈 What is it?
Net Debt shows how much debt remains after subtracting a company’s available cash reserves.
🧮 How is it calculated?
🏛️ Why is it important?
It indicates how dependent a company is on borrowed money and how easily it can service its debt in the short term.
🧮 Calculation
🎯 What does this mean for investors?
- Low or negative net debt signals financial strength and flexibility.
- Companies with strong cash positions are better positioned in crises.
- High net debt increases financial risk — especially in environments with rising interest rates or economic downturns.
📘 Cash
📈 What is it?
Cash represents all liquid assets a company can access immediately — including cash, bank deposits, and short-term investments.
🧮 How is it calculated?
🏛️ Why is it important?
It reflects a company’s financial flexibility and resilience — enabling investments, buybacks, or buffer in downturns.
🧮 Calculation
🎯 What does this mean for investors?
- A strong cash position means greater room for maneuver and crisis resistance.
- Cash-rich companies can invest, pay down debt, or repurchase shares.
- But excess idle cash might indicate a lack of growth opportunities.
📘 Shares Outstanding
📈 What is it?
Shares outstanding represent the total number of a company’s shares currently held by investors — excluding treasury stock.
🧮 How is it calculated?
🏛️ Why is it important?
It’s the basis for key metrics like Earnings Per Share (EPS), Market Capitalization, or the Price/Earnings ratio (P/E).
🧮 Calculation
🎯 What does this mean for investors?
- Fewer shares in circulation typically increase earnings per share — making each share more valuable.
- Share buybacks reduce the number of shares and boost per-share metrics.
- Issuing new shares does the opposite — diluting shareholder value and lowering per-share figures.
📘 Price-to-Earnings Ratio (P/E)
📈 What is it?
The P/E ratio shows how many times a company's earnings per share are reflected in its current share price — in other words, how "expensive" the stock appears relative to its profits.
🧮 How is it calculated?
🏛️ Why is it important?
The P/E ratio is one of the most widely used valuation metrics. It helps investors assess whether a stock appears cheap or expensive compared to its earnings power.
🧮 Calculation
📊 P/E (TTM) = Based on earnings from the last 12 months (Trailing Twelve Months):🎯 What does this mean for investors?
- A low P/E may indicate undervaluation — or signal underlying issues.
- A high P/E may reflect strong growth expectations — or an overvalued stock.
📘 Price-to-Sales Ratio (P/S)
📈 What is it?
The P/S ratio shows how much investors are paying for $1 of the company’s revenue – regardless of profitability.
🧮 How is it calculated?
🏛️ Why is it important?
P/S is especially useful for evaluating growth companies or businesses not yet profitable. It reflects how the market values the company’s sales.
🧮 Calculation
Market Cap = $775.03m | Revenue (TTM) = $28.73m
Market Cap = $775.03m | Estimated Revenue = $94.00m
🎯 What does this mean for investors?
- A low P/S may indicate undervaluation — or low profitability.
- A high P/S can reflect strong growth expectations — or excessive optimism.
- Especially helpful when evaluating companies where profits are low, volatile, or negative.
📘 Enterprise Value to Sales (EV/Sales)
📈 What is it?
EV/Sales shows how much investors are paying for $1 of revenue — considering not just equity, but also debt and cash. It’s the capital structure–adjusted version of the P/S ratio.
🧮 How is it calculated?
🏛️ Why is it important?
It’s ideal for comparing companies with different levels of debt. It reflects a company's true cost relative to its revenue.
🧮 Calculation
Enterprise Value = $153.93m | Revenue (TTM) = $28.73m
Enterprise Value = $153.93m | Forward Revenue = $94.00m
🎯 What does this mean for investors?
- EV/Sales allows for capital structure–neutral company comparisons.
- A lower ratio may indicate undervaluation; a higher one may signal strong growth expectations or overvaluation.
- Especially helpful when evaluating high-growth companies with low or negative earnings.
📘 Enterprise Value to Free Cash Flow (EV/FCF) | ex SBC
📈 What is it?
EV/FCF compares a company’s enterprise value with its free cash flow. The metric therefore shows the multiple of current free cash flow at which a company is valued. EV/FCF ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted version.
🧮 How is it calculated?
EV/FCF ex SBC = Enterprise Value ÷ (Free Cash Flow (TTM) − SBC)
🏛️ Why is it important?
EV/FCF provides a valuation based on free cash flow and therefore complements earnings-based valuation metrics such as the P/E ratio. The ex SBC version additionally accounts for the economic impact of stock-based compensation and provides a more conservative view from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A low EV/FCF means that enterprise value is low relative to current free cash flow. The reasons should always be considered in the context of the company and its industry.
- A high EV/FCF means that enterprise value is high relative to current free cash flow. This can, for example, reflect high growth expectations or temporarily weak cash generation.
- When SBC is positive and adjusted free cash flow remains positive, EV/FCF ex SBC is generally higher than the standard EV/FCF.
- The metric is particularly useful for companies with relatively stable and predictable cash flows.
- If free cash flow is negative or very low, EV/FCF has limited usefulness and should not be interpreted like a standard valuation multiple.
📘 Price-to-Book Ratio (P/B)
📈 What is it?
The P/B ratio compares a company’s market value to its book value — showing how much investors are paying for each dollar of net assets.
🧮 How is it calculated?
🏛️ Why is it important?
P/B is commonly used for asset-heavy industries like banks or industrials. It helps assess whether a stock is trading above or below its net asset value.
🧮 Calculation
🎯 What does this mean for investors?
- A P/B below 1 may signal undervaluation — or weak profitability.
- A P/B above 1 implies the market expects future value creation (e.g., brand, IP, growth).
- Best used for companies with tangible assets and strong balance sheets.
📘 Equity Ratio
📈 What is it?
The equity ratio indicates what portion of a company’s total assets is financed by shareholders’ equity – in other words, how much it relies on its own capital.
🧮 How is it calculated?
🏛️ Why is it important?
A high equity ratio reflects financial strength and stability, especially during downturns. It’s a key indicator of a company’s solvency and long-term risk profile.
🧮 Calculation
🎯 What does this mean for investors?
- Companies with high equity ratios are generally more resilient and less dependent on external debt.
- Low equity ratios can signal higher risk or aggressive financial strategies.
- Important: Always assess the equity ratio in combination with the return on equity (ROE). This shows not just how stable the company is – but also how efficiently it uses shareholder capital.
📘 Return on Equity (ROE)
📈 What is it?
Return on equity (ROE) shows how efficiently a company uses its shareholders’ equity to generate profit. In other words: how much net income is earned per dollar of equity.
🧮 How is it calculated?
🏛️ Why is it important?
ROE is a core profitability metric. It helps investors understand whether a company delivers attractive returns on the capital provided by its shareholders.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROE indicates that the company is using its capital efficiently and profitably.
- It’s especially meaningful for capital-intensive businesses or firms with high equity bases.
- Important: A very high ROE can also result from high debt levels – always interpret it alongside the equity ratio to assess financial health.
📘 Return on Capital Employed (ROCE)
📈 What is it?
ROCE measures how efficiently a company generates profits from its total capital – including both equity and interest-bearing debt.
🧮 How is it calculated?
It evaluates the return on all capital employed, regardless of how it’s financed.
🏛️ Why is it important?
ROCE is ideal for comparing companies with different financing structures. It shows how well management uses capital to create value for both shareholders and creditors.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROCE means the company uses its capital efficiently – regardless of whether it's funded by debt or equity.
- The higher the ROCE compared to peers, the more value the company creates with its invested capital.
- Especially relevant for capital-intensive sectors like industrials, energy, or infrastructure.
📘 Return on Invested Capital (ROIC)
📈 What is it?
ROIC measures how efficiently a company generates returns from the capital invested in its core operations – regardless of whether the capital comes from equity or debt.
🧮 How is it calculated?
- NOPAT = Net Operating Profit After Taxes
- Invested Capital = Operating assets minus non-interest-bearing liabilities
🏛️ Why is it important?
ROIC is one of the most accurate indicators of capital efficiency. Unlike return on equity, it is not distorted by leverage and shows how much value is created for all capital providers.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROIC shows how effectively a company uses the capital that is truly invested in its core operations.
- Unlike ROCE, ROIC focuses only on the capital that is actively used to run the business – and that requires a return (i.e. interest-bearing).
- Especially useful when comparing companies with large amounts of excess cash or non-interest-bearing liabilities – giving a more realistic picture of capital efficiency.
📘 Leverage Ratio (Debt-to-Equity)
📈 What is it?
The leverage ratio indicates how much a company relies on interest-bearing debt (such as loans and bonds) relative to its shareholders’ equity.
🧮 How is it calculated?
🏛️ Why is it important?
This ratio helps assess a company’s financial structure and risk profile. High leverage can enhance returns – but also increases exposure to interest rate changes and financial stress.
🧮 Calculation
🎯 What does this mean for investors?
- A low leverage ratio signals financial strength and independence.
- A higher ratio can improve returns in good times but increases risk during downturns or rising interest rate periods.
- 👉 Always interpret in the context of industry, capital intensity, and interest rate environment.
📘 SBC | in % Revenue
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to revenue.
🧮 How is it calculated?
SBC as % of Revenue = (SBC ÷ Revenue) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of revenue shows how heavily a company relies on equity-based compensation and how significant this form of compensation is relative to the size of the business.
🧮 Calculation
🎯 What does this mean for investors?
- A lower figure is generally positive: Stock-based compensation is relatively small compared with the company's revenue.
- A high figure can indicate greater reliance on stock-based compensation and a higher potential risk of dilution. However, it is also important to consider whether the company offsets dilution through share buybacks.
- The trend over time should also be considered. A high but declining percentage presents a different picture from a persistently high or increasing percentage.
- A single-digit SBC-to-revenue ratio is not unusual among many growth-oriented and technology companies.
📘 SBC as % of FCF
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to free cash flow (FCF).
🧮 How is it calculated?
SBC as % of FCF = (SBC ÷ Free Cash Flow) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of free cash flow shows how significant SBC is relative to the cash generated by the company. Since SBC is non-cash compensation, it is typically not deducted as a cash outflow when calculating FCF.
🎯 What does this mean for investors?
- A lower value is generally favorable. Stock-based compensation is relatively small compared with the company's cash generation.
- A high value means that SBC represents a significant portion of the company's reported free cash flow, even though SBC itself is non-cash.
- The higher the value, the more significant SBC can be as an economic cost to shareholders, particularly when it results in share dilution.
📘 SBC Growth 1Y
📈 What is it?
SBC Growth 1Y shows how much a company's stock-based compensation has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
SBC Growth shows whether stock-based compensation is becoming more or less significant for shareholders. If SBC increases significantly, it can lead to greater shareholder dilution over time. At the same time, SBC is a non-cash expense that reduces earnings on the income statement but is added back in the cash flow statement.
🧮 Calculation
🎯 What does this mean for investors?
- A high positive value is generally negative, as rising SBC can increase the burden on shareholders, particularly through potential dilution.
- What matters is whether the development of SBC is sustainable over the long term. Some level of SBC is common among many growth and technology companies.
📘 Share Count Growth 1Y
📈 What is it?
Share Count Growth 1Y shows how much the number of shares outstanding has increased or decreased over a one-year period.
🧮 How is it calculated?
🏛️ Why is it important?
The number of shares determines how many shares the company's earnings and assets are distributed across. If the share count decreases, existing shareholders' relative ownership increases. If it increases, existing shareholders are diluted. The metric therefore makes dilution and share buybacks directly visible.
🧮 Calculation
🎯 What does this mean for investors?
- A negative value is generally positive, as the number of shares outstanding is decreasing.
- A positive value indicates dilution of existing shareholders.
- A declining share count is not automatically positive: It also matters at what price the shares are repurchased and how the buybacks are financed.
📘 Shareholder Yield
📈 What is it?
Shareholder Yield measures how much capital a company returns to shareholders through dividends and share buybacks, relative to its market capitalization. It goes beyond dividend yield by also including share buybacks.
🧮 How is it calculated?
🏛️ Why is it important?
Dividend yield only tells part of the story. When a company buys back shares and the share count falls, each existing shareholder owns a larger part of the company. When the share count rises, for example through stock-based compensation or new share issuance, existing shareholders are diluted. Shareholder Yield combines both into one metric.
🧮 Calculation
🎯 What does this mean for investors?
- A higher Shareholder Yield indicates more capital being returned to shareholders.
- A negative value means the company issued more new shares than its dividends and buybacks make up for.
- Share buybacks are most beneficial when shares are repurchased at attractive valuations.
- Investors should also consider whether dividends and buybacks are sustainable over time.
📘 Revenue
📈 What is it?
Revenue shows how much a company earns in total from selling its products and services – the gross income before any costs are deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Revenue is one of the key figures to assess a company’s size, market position, and growth potential.
🧮 Calculation
🎯 What does this mean for investors?
- Growing revenue indicates rising demand and can be an early signal of future earnings growth.
- Comparing actual and expected revenue reveals trends in the market environment and analyst sentiment.
- Note: Strong revenue alone isn’t enough – margins and profitability matter just as much.
📘 EBITDA
📈 What is it?
EBITDA stands for “Earnings Before Interest, Taxes, Depreciation, and Amortization.” It reflects a company’s operating profit before the effects of financing, taxes, and accounting depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
EBITDA is widely used to evaluate a company’s operating performance – especially across capital-intensive sectors or international comparisons.
🧮 Calculation
🎯 What does this mean for investors?
- A high or growing EBITDA indicates strong operational profitability – independent of taxes, interest, or accounting methods.
- It’s especially useful for comparing companies across sectors or geographies.
- Important: EBITDA is not a net income figure – it excludes key costs like depreciation and interest.
📘 EBIT
📈 What is it?
EBIT stands for “Earnings Before Interest and Taxes.” It reflects a company’s operating profit after depreciation, but before interest and tax expenses.
🧮 How is it calculated?
🏛️ Why is it important?
EBIT is a core profitability metric that shows how well the company performs in its main business operations – independent of capital structure and tax environment.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT indicates strong profitability from the company’s core business – before financial and tax effects.
- It allows better comparison between companies with different debt levels or tax structures.
- Compared to EBITDA, EBIT already accounts for depreciation and reflects capital intensity more clearly.
📘 Net Income
📈 What is it?
Net income is the company’s total profit – the amount left after all expenses, taxes, interest, and depreciation have been deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Net income is the most comprehensive measure of a company’s profitability – showing how much actual profit remains after all business and financing costs.
🧮 Calculation
🎯 What does this mean for investors?
- Growing net income indicates that the company is managing all of its costs efficiently.
- It directly influences valuation metrics like P/E ratio and the company’s dividend capacity.
- Over time, net income trends reveal how resilient and profitable the business model really is.
📘 Free Cash Flow (FCF) | ex SBC
📈 What is it?
Free cash flow shows how much cash remains after a company has covered its operating and capital expenditures. FCF ex SBC additionally deducts stock-based compensation (SBC) to adjust the cash flow for the effect of non-cash SBC.
🧮 How is it calculated?
Free Cash Flow ex SBC = Operating Cash Flow − SBC − Capital Expenditures (CAPEX)
🏛️ Why is it important?
FCF reflects a company’s actual financial strength – independent of reported accounting earnings. It shows how much flexibility a company has for dividends, share buybacks, or debt reduction. FCF ex SBC also deducts stock-based compensation and shows how much cash generation remains after SBC.
🧮 Calculation
🎯 What does this mean for investors?
- High free cash flow indicates that a company has strong financial strength – independent of reported earnings.
- It is often a solid basis for sustainable dividends and share buybacks.
- Declining FCF can be a warning sign, even if reported earnings remain stable.
📘 Revenue Growth
📈 What is it?
Revenue growth shows how much a company’s sales have changed compared to the previous year – both on a trailing basis (TTM) and based on forward projections.
🧮 How is it calculated?
Forward = (Expected revenue ÷ Revenue in prior year − 1) × 100
Forward growth is based on analyst estimates for the current fiscal year.
🏛️ Why is it important?
Rising revenue signals growing demand, business expansion, and market share gains – especially important for growth-oriented companies.
🧮 Calculation
🎯 What does this mean for investors?
- Growth is the engine of long-term value creation – especially in tech and growth sectors.
- What matters is not just current growth, but its sustainability.
- Forward projections reflect whether analysts expect continued momentum – or a slowdown.
📘 EBITDA Growth
📈 What is it?
EBITDA growth shows how much a company’s operating profit (before interest, taxes, depreciation, and amortization) has increased or decreased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBITDA ÷ EBITDA from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
Growing EBITDA indicates improving operational profitability – regardless of financing or accounting effects.
🧮 Calculation
🎯 What does this mean for investors?
- Strong EBITDA growth signals operational efficiency and scalability – especially during growth phases.
- EBITDA growth can be an early indicator of margin and earnings expansion – but should be assessed alongside revenue and EBIT.
📘 EBIT Growth
📈 What is it?
EBIT growth shows how much a company’s operating profit (after depreciation, but before interest and taxes) has increased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBIT ÷ EBIT from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
EBIT growth is a direct indicator of a company’s business performance – taking into account capital intensity through depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- Rising EBIT signals improving operating profitability – even after accounting for depreciation.
- It’s especially important for evaluating companies with significant capital expenditures.
- Combined with revenue and EBITDA growth, EBIT growth provides a well-rounded view of operational progress.
📘 Net Income Growth
📈 What is it?
Net income growth shows how much a company’s bottom-line profit has increased or decreased compared to the previous year – both on a trailing basis (TTM) and based on analyst projections.
🧮 How is it calculated?
Forward = (Expected net income ÷ Net income from prior year − 1) × 100
The forward estimate reflects analysts’ expectations for the current fiscal year.
🏛️ Why is it important?
Net income is the ultimate measure of profitability. Growing net income signals stronger efficiency, cost control, and sustainable earnings power.
🧮 Calculation
🎯 What does this mean for investors?
- Stronger net income boosts valuation, dividend potential, and investor confidence.
- If profits stall while revenue grows, it may signal margin pressure.
📘 Free Cash Flow Growth
📈 What is it?
Free cash flow (FCF) growth shows how a company’s available cash – after covering operating expenses and capital expenditures – has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
Free cash flow reflects real financial strength. Growing FCF indicates more flexibility for dividends, share buybacks, and reinvestment.
🧮 Calculation
🎯 What does this mean for investors?
- Declining FCF may point to rising investments, increasing costs, or weaker operating performance.
- Especially for dividend investors, FCF growth is critical – since dividends are paid from actual available cash.
- A negative trend isn't always bad, but it deserves closer attention.
📘 Gross Margin
📈 What is it?
Gross margin shows how much of a company’s revenue remains after deducting the direct costs of goods sold (like materials and production). It represents the company’s “raw profit” before fixed costs, taxes, and interest.
🧮 How is it calculated?
Or simply: Gross Margin = Gross Profit ÷ Revenue × 100
🏛️ Why is it important?
Gross margin indicates how efficiently a company can produce or procure what it sells. It is a key measure of product-level profitability and pricing power.
🎯 What does this mean for investors?
- A high gross margin suggests strong pricing power and efficient production.
- Falling margins may signal rising input costs or competitive pressure.
- Compared to peers, gross margin offers insights into the quality of a business model.
📘 EBITDA Margin
📈 What is it?
The EBITDA margin shows how much of a company’s revenue remains as operating profit before interest, taxes, depreciation, and amortization.It reflects operating efficiency without being distorted by financing or accounting factors.
🧮 How is it calculated?
🏛️ Why is it important?
The EBITDA margin reveals how much operating income a company generates per dollar of revenue – independent of capital structure and tax effects.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBITDA margin reflects strong core profitability – before accounting distortions.
- It allows for effective comparisons across companies and sectors.
- A stable or growing margin signals efficient cost control and business scalability.
📘 EBIT Margin
📈 What is it?
The EBIT margin shows what percentage of revenue remains as operating profit after depreciation but before interest and taxes.
🧮 How is it calculated?
🏛️ Why is it important?
The EBIT margin reflects a company’s core profitability while accounting for capital intensity (e.g. machinery, infrastructure). It’s especially useful for comparing businesses with different levels of depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT margin shows that the company remains efficient even after factoring in depreciation.
- It’s especially relevant for capital-intensive industries.
- Stable or rising EBIT margins over time are a strong indicator of pricing power and business quality.
📘 Net Margin
📈 What is it?
Net margin shows how much of a company’s revenue remains as bottom-line profit after deducting all costs, interest, taxes, and depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
Net margin reflects a company’s overall efficiency – across operations, financing, and taxation. It shows how much actual profit is generated from each dollar of revenue.
🧮 Calculation
🎯 What does this mean for investors?
- A high net margin means the company is not only strong operationally but also manages financing and taxes efficiently.
- Peer comparisons reveal business quality and competitiveness.
- Declining margins despite revenue growth can be a red flag for rising costs or inefficiencies.
📘 Free Cash Flow Margin | ex SBC
📈 What is it?
The Free Cash Flow Margin shows how much free cash flow a company generates relative to its revenue. In simplified terms, free cash flow is calculated as operating cash flow minus capital expenditures. The Free Cash Flow Margin ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted metric.
🧮 How is it calculated?
Free Cash Flow Margin ex SBC = (Free Cash Flow − SBC) ÷ Revenue × 100
🏛️ Why is it important?
The Free Cash Flow Margin shows how efficiently a company converts its revenue into free cash flow. Strong free cash flow can provide financial flexibility for dividends, share buybacks, debt repayment, or further investments. The ex SBC version additionally accounts for the economic impact of stock-based compensation and therefore provides a more conservative view of cash generation from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A high Free Cash Flow Margin shows that a company converts a high proportion of its revenue into free cash flow.
- This can provide greater financial flexibility for dividends, share buybacks, debt repayment, or investments.
- The Free Cash Flow Margin ex SBC additionally accounts for potential shareholder dilution from stock-based compensation.
- The long-term trend is particularly important. Declining margins can, for example, result from higher investments, changes in working capital, or weaker operating performance.
📘 Earnings per share (EPS)
📈 What is it?
Earnings per Share (EPS) shows how much profit is attributable to a single share – and is one of the most important metrics for evaluating a company's performance.
🧮 How is it calculated?
The diluted share count reflects potential new shares that could be issued through options, convertible bonds, or other rights.
🏛️ Why is it important?
EPS is the basis for many key valuation metrics like P/E ratio, PEG ratio, or payout ratio. It enables comparisons of profitability across companies, regardless of their size.
🧮 Calculation
🎯 What does this mean for investors?
- EPS captures per-share profitability and is especially useful for comparisons over time or with analyst estimates.
- Rising EPS may signal consistent growth or share buybacks.
- Important: Always use diluted EPS for more realistic valuations – especially in companies with stock-based compensation.
📘 Free cash flow per share (FCF per share)
📈 What is it?
Free Cash Flow per Share shows how much free cash flow a company generates per outstanding share – after investments, but before dividends or debt repayments.
🧮 How is it calculated?
Free cash flow is calculated as operating cash flow minus capital expenditures (CapEx).
🏛️ Why is it important?
FCF per Share reveals how much real cash is available per share – useful for dividends, buybacks, or reducing debt. Unlike net income, free cash flow is harder to manipulate and often seen as a more reliable metric.
🧮 Calculation
🎯 What does this mean for investors?
- High FCF per share signals strong financial flexibility.
- It shows how much capital the company can effectively reinvest or return to shareholders.
- Particularly relevant for dividend payers and capital-efficient businesses.
📘 Short interest
📈 What is it?
Short interest indicates how many shares of a company are currently sold short – that is, borrowed and sold by investors who expect the price to decline.
🧮 How is it calculated?
It reflects the percentage of a company’s shares that are being shorted relative to the total shares available.
🏛️ Why is it important?
Short interest serves as a sentiment indicator: A high value may signal skepticism or bearish expectations – but also increases the potential for a short squeeze if prices rise unexpectedly.
🧮 Calculation
🎯 What does this mean for investors?
- Low short interest usually indicates market confidence in the company.
- High short interest can be a warning sign – or an opportunity if sentiment shifts.
- Especially relevant in volatile markets or ahead of key earnings releases.
📘 Employees
📈 What is it?
The employee count shows how many people a company employs worldwide – offering insights into its size, structure, and business model.
🧮 How is it calculated?
🏛️ Why is it important?
It helps assess operational scale, labor intensity, and cost structure. Combined with revenue and profit, it enables key metrics like revenue per employee or productivity.
🧮 Calculation
🎯 What does this mean for investors?
- A high headcount can signal operational complexity – but also significant growth capacity.
- Revenue per employee is a key indicator of efficiency.
- Especially useful for comparing tech, industrial, or service-heavy companies.
📘 Revenue per employee
📈 What is it?
Revenue per employee indicates how much revenue a company generates on average per employee – a key measure of efficiency and productivity.
🧮 How is it calculated?
The employee count is typically taken from the most recent annual report.
🏛️ Why is it important?
This metric helps compare business models – especially between labor-intensive and technology-driven companies. A high value suggests automation, operational efficiency, or strong value creation per head.
🧮 Calculation
🎯 What does this mean for investors?
- A high revenue per employee indicates a scalable and margin-strong business model.
- A low figure may reflect labor-intensive operations or lower value-add.
- Especially helpful when comparing tech companies to industrial or service sectors.
Monte Rosa Therapeutics Inc Stock Analysis
Analyst Opinions
16 Analysts have issued a Monte Rosa Therapeutics Inc forecast:
Analyst Opinions
16 Analysts have issued a Monte Rosa Therapeutics Inc forecast:
Monte Rosa Therapeutics Inc Events
Past Events
|
NOV
16
UBS Global Biopharma Conference 2026
2 days ago
|
|
OCT
1
Special Call - Monte Rosa Therapeutics, Inc.
about 2 months ago
|
StocksGuide Free
Monte Rosa Therapeutics Inc — UBS Global Biopharma Conference 2026
1. Question Answer
Okay. Good morning, everybody. Good afternoon. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the SMID biotech analysts at UBS. Happy to introduce Monte Rosa Therapeutics. We have with us Markus Warmuth, Chief Executive Officer. Great to see you, Markus. Thank you so much for joining us.
Great to see you, and thanks for inviting us to your conference here.
Yes, absolutely. So to start with, would you like to give a brief overview of the company and of your QuEEN molecular glue degrader platform for those who may be newer to the story, and then we can get into some Q&A.
Yes, happy to. And so Monte Rosa is still a fairly young company. We're about 7 years old now. You can tell from the name we originated in Switzerland, although we're now headquartered in the U.S. And we're doing targeted protein degradation. As you know, there's different ways of doing it. There's a modality called PROTACs. That's what we're not doing, sort of heterobifunctional molecules that bind to the protein destruction complex and something you want to destroy.
Our molecules are a bit more complex, so they're technically smaller. They're small molecules that essentially bind to a ubiquitin ligase, which is part of that protein destruction complex, and then reshape its surface to induce a protein-protein interaction with the target we want to get rid of. And so for us, really, opened up a lot of opportunities around targets that others are just like flat out not able to go after. VAV1, which we probably will touch on, is one of the best examples for that.
Great. So I wanted to start with MRT-8102, which is your wholly owned NEK7 degrader moving into Phase II. So just to start with, when you think about NEK7 degradation versus direct NLRP3 inhibition, what are the key advantages of your approach? And are you aiming to achieve better efficacy or safety or?
Yes. So we're now in the NLRP3 inflammasome, which obviously is a hot pathway, also a contested one, which I'm sure we will talk about in a second. There's 2 ways you can sort of inhibit the NLRP3 inflammasome: you have a direct inhibitor or, as in our case, a NEK7 degrader. What does a NEK7 degrader, 8102, do? NEK7 actually is an essential scaffolding protein for the NLRP3 inflammasome. So essentially, if there's no NEK7, there's no active, fully assembled inflammasome. And we sort of like that, of course, better than the on-and-off inhibition that you get with inhibitors.
We also do think that provides for better safety margins because we can make our degraders exquisitely selective, and we can actually test it on a cellular level through proteomics. We know that 8102 degrades NEK7 and nothing else across multiple different cell types we have tested. For NLRP3 inhibitors, best case, you have some other ATPase biochemical assays, but you really can't test selectivity across 10,000, 20,000 proteins in the cell. And so we're super, super confident in general when we go into the clinic about the level of selectivity and then, of course, also safety. The last point to make is when you degrade, the protein is gone, the pathway is shut down, doesn't necessarily -- typically not come back. And so you do get much deeper, more prolonged PD, which obviously we think will translate into better efficacy.
Great. Now very topical is the ZEUS data set. It was recently at AHA, the full data set from Novo Nordisk with the IL-6 program, which was very relevant to you guys in the broader NLRP3 space as well. Kind of it will be interesting to hear your perspective on that and the implications for upstream approaches, including your approach.
Yes. I mean, obviously, ZEUS and the data release sent shock waves through the field. I will always remember the data was July 31. That's how dramatic this was for us. That said, we were always a little skeptical around sort of the IL-6 targeting. If you think about the pathway in the NLRP3 pathway, IL-6 is like very far downstream. It's literally like the last step before you essentially synthesize and release CRP from the liver, and it was unclear to us how that feeds back into active inflammation in atherosclerotic plaques.
Now, kind of, a week or 2 after the actual data was presented at AHA, I think it became or is even more clear why the trial didn't succeed. And I think it's really a combination of what I've just said, maybe not the best target to go after, plus maybe not the best drug. It was interesting to see that the antibody left about 25% IL-6 in the system. So it reduced IL-6 levels by 75%. I would have expected 90% and greater for an antibody.
And then there were clearly some issues around -- actually not some, big issues around the trial design. I think there was an obsession around selecting for high CRP levels, probably that led to the idea of selecting patients with chronic kidney disease, CKD -- that alone actually, of course, increases your CRP levels. Many of the patients, the majority -- vast majority, were obese. So you now have inflammation coming from the liver. And of course, when you end up with a CRP level of greater than 3 milligrams per liter, now you don't know, okay, how much is from the kidney, from the liver or an active atherosclerotic plaque, and many of the patients going into this trial might not even have had an ongoing ASCVD issue.
And I think between these 3 things, probably not a shocker that the trial was negative, which translates into -- we still have very, very high conviction around the pathway, the level of validation between, like, increased lipids, oxidized LDL, oxidized cholesterol and triggering the NLRP3 pathway is rock solid. And I think if you have the right trial design, you really find the patients that still have remaining inflammatory risk in ASCVD, we'll be absolutely successful.
And after AHA, I know there was also some conversation about this at ESC. Do you feel like industry and physician community are kind of coming around to the idea that NLRP3 and NEK7 should be interrogated as the next target? Or is that kind of slower moving?
It feels that -- and to be honest, I mean, even post-ZEUS, I understand why, right? I think investors reacted like, 'Okay, it's over,' right? Like inflammation has been invalidated. We never had that feeling, that negativity talking to our KOLs or even the strategics we interact with on a fairly regular basis. I think everyone just came to the conclusion, okay, IL-6 maybe not the right target, or some pharma companies are even still like hanging on to that. But if you do go upstream, this should eventually be working.
And I think the best document for that is -- since ZEUS, I think Novartis started a Phase II trial in ASCVD with their next-generation NLRP3 inhibitor. Roche has now started 1 with their next-generation NLRP3 inhibitor. Novo actually has started a Phase I with an NLRP3 inhibitor, obviously with an intention to then go into a Phase II. It's unclear yet what Lilly will do with the Ventyx asset, but they're probably also going to land at some point, sort of, somewhere between metabolic disease and ASCVD. And so I think the conviction in strategics around the pathway targeting upstream is extremely high, as high as ours.
So they're getting it. Okay. I think investors are wondering sort of what is the next kind of catalyst in this? What is the next important development in the NLRP3/NEK7 space in cardiovascular disease? Is it going to be a pharma company starting a cardiovascular outcomes trial? Is it going to be something else? What are your thoughts on that?
Well, hopefully, our G-FORCE-2 study, right, when it delivers, sort of, a clear context for how this could work. Obviously, in G-FORCE-1, we had also somewhat simplified the population we were going after. But keep in mind, that wasn't a cardiovascular outcomes study, right? That was a sort of Phase I safety PK/PD study.
And so what we are now trying to do in our Phase II is really within coronary artery disease, so probably the most important subgroup of ASCVD, establish a correlation between inflamed atherosclerotic plaques determined by imaging and then the types of biomarkers we can modulate and genetics because there's really also very strong genetics around the NLRP3 inflammasome. I do think pharma companies also going down the path and starting Phase IIIs can certainly help with conviction around the pathway as well.
So why don't we talk a bit then about your recent G-FORCE-1 data and why that was interesting and the additional biomarkers that you showed there as well. And then we can talk about your G-FORCE-2 trial as well in more detail.
Yes. So I mean, as I said, G-FORCE-1, sort of -- I was about to say classical Phase I study, but it really wasn't because it was more than SAD/MAD, right? We've added this sort of extended 4-week cohorts with subjects at risk of developing cardiovascular disease. The way to find these, obviously, was to look for obese patients, which now is, sort of, a little bit contradictory to, like, I was trashing Novo for selecting too many obese. But again, for us, it was mostly just finding a population where biomarkers were elevated to a point where we could show within 4 weeks that we could bring them down.
I think the most important difference to what many others have done is we went way broader in biomarkers because sure -- and I still think CRP is a great biomarker. It's not a causal biomarker, though, right? So sometimes you will bring it down and it's like it doesn't matter, and then sometimes you bring it down, but you hit the right node and it actually does matter. But we went much broader. We were focused quite a bit on what's called DAMPs. So these are more local mediators of inflammation. Many of these actually have been shown to be down-modulated in ASCVD by lipid-lowering drugs as well as inflammation goes away.
Probably some of the best known are calprotectin and HMGB1. And for each of these, we were actually able to show that they basically go -- go back to normal physiological levels. So really encouraging. Obviously, in that study, we haven't used imaging yet for atherosclerotic plaques. Probably also wouldn't have made much sense, why? Because within 4 weeks, it's hard to expect to see any meaningful differences by imaging. But yes, we were certainly extremely pleased with the outcome. Also worth mentioning that in this study, we dosed between 5 milligrams and 40, and we saw similar levels of biomarker modulation between these different cohorts, so essentially establishing a pretty wide range of doses that we can now work with.
Great. And with G-FORCE-2, I know you're not the only company to go into coronary artery disease. So why does this indication or patient population make the most sense as the next step?
Yes. I mean if you look at the aggregate of all work that's been done in ASCVD, this goes back to Novartis' canakinumab trial, where you could argue even going back to some of the trials with lipid-lowering drugs. You look at some of the cardiovascular outcome trials for GLP agonists, I think the common denominators are like sure, coronary artery disease is probably the subgroup -- it's the most important, the bigger subgroup, but also the 1 where your efficacy seems to be most predictable. And I think that has to do with sort of the makeup of those atherosclerotic plaques and how modifiable they are.
It was interesting to see, and we've heard this a few times from investors, why not go after peripheral artery disease? In ZEUS, that was literally the worst of all subgroups. It was a small subgroup and the hazard ratio, and I'm not saying it was statistically significant, but the reported hazard ratio there, I think, was 1.3. That makes 0.97 look really good, right? And so it just tells you there are just like subtypes of ASCVD that are probably a little bit too messy to think you can be successful in an outcomes trial.
And you're using coronary artery imaging and the fat attenuation index. Can you talk a bit about those and how important those are in terms of kind of identifying patients who have the type of inflammation that you're looking for?
Yes. So we believe this will be very important at the very least in sort of identifying patients with active ongoing inflammation in plaques. This is essentially how the method has been established. I mean the sort of standard of care CTs, but like sort of a different way of analyzing those images. Great study, I think, like 40,000 patients essentially establishing that when you are positive for FAI, you have a tremendously increased risk of mortality. I think it was like a close to 30-fold increase.
It hasn't really been used yet to assess efficacy. There's a few trials that are ongoing that will sort of tell us on how much you can actually also lower FAI and predict future cardiovascular outcome. But for finding the truly inflamed patients that carry sort of residual risk even in sort of an optimal sort of lipid-lowering setting, I think this will be a game changer.
I'm just curious, is this something that could be rolled out on a larger scale, this type of imaging to identify patients? Or will we still rely on hsCRP?
No. I mean I think this will pretty much become standard of care for coronary artery disease. Now hsCRP for therapeutic response, I think, will remain very important because, again, we still have to establish that for FAI, I mean how much that actually predicts outcome. I think for hsCRP, despite ZEUS' failure, we have it because let's not forget, like CANTOS as the trial for canakinumab showed that correlation, right?
So I think for hsCRP, it can be very predictive if you go after the right node in the pathway. IL-6 wasn't the right node in the pathway. And two, hsCRP is extremely easy to measure wherever you live in the world. So I think this will remain an important assay, but you do have to sort of establish that correlation, of course.
So for the G-FORCE-2 study, remind us, what are the timelines for this study? And what do you really need to show for that readout?
Yes. I mean timelines are fairly simple. I think we've guided to a start first half of next year. Obviously, we're trying to get this off the ground as early as possible next year. The outcome here, again, this will be 6 months of treatment, right? So it won't be an outcomes trial. What we really want to see is sort of an established correlation between that fat attenuation index and some of the more proximal biomarkers we've talked about, right, like DAMPs, whether there is a good correlation with hsCRP to be determined because, as I said, there's other things that can lead to CRP increases, right? And so I think this will be very telling at the end of the day.
I think if we then also see a reduction in the fat attenuation index after 6 months, even better. We've also mentioned that we're looking into genetics. There are some interesting results and we had a little bit of that in our disclosure around SNPs in NLRP3 and increased biomarkers indicating increased inflammation in those patients. And so this is really the correlations you want to establish, right? FAI, proximal biomarkers, and how all of this correlates to NLRP3 genetics.
Okay. Great. And you have a couple of other indications, I think, with this asset, gout and HS. Could you maybe talk about those trials and the time lines there? And I think we might be getting the gout trial readout ahead of the CAD readout. So what can you learn from that one that could inform the CAD?
Yes. I mean gout sort of somewhat different, also interestingly on a pathology signaling point of view, very similar, right, like both gout and ASCVD are induced or the pathway is induced by crystals. Here, it's MSU crystals, so urate crystals that form in those patients and then trigger the pathway and then inflammation.
The upside on gout, of course, is sure there's a fairly easy clinical readout even in the Phase II. It's avoidance of flares. And so our Phase II here is going to be fairly simple, small, 60 patients, 2 dose cohorts, essentially looking to prevent recurrent flares after management of an acute flare.
There's lots of proof of concept for the pathway in gout, including canakinumab, but even better, there is a small molecule that's being used, although it has lots of side effects, with colchicine. And so hopefully, when this reads out second half of next year, it will be positive and sort of pave a path into really substantial broad use of 8102 in the future. Obviously, we have to do a Phase III trial there next.
For HS, this will likely be the third trial to start. Guidance is also first half of next year, but it will likely be after the -- after G-FORCE-2. Obviously, a space that's becoming a little bit more clouded as well, right, with some of the recent -- not necessarily negative readouts, but readouts that weren't as positive as hoped for, mostly because of overperforming placebo arms, but then also interesting drops in activity for the active arm between Phase IIs and Phase IIIs.
Some interesting observations there also. I mean, we've looked at a lot of the data over the last 5 years systematically. Many of the Phase IIs actually had shown inverse dose responses, which we're trying to understand. And so some more work for us to do in preparing that trial before we can kick it off.
Very interesting. Why don't we move to your VAV1 degrader then, which you -- it's 6160, which you have partnered with Novartis. And maybe we can start with why is VAV1 an exciting target. It seems like you're one of the only companies pursuing this.
Yes. So VAV1, we're just like super excited about. It does fall into this category of absolutely undruggable target proteins. No one has ever been able to find a ligand, no one has ever been able to find an inhibitor, and we know many pharma companies tried for a long time, and that actually includes Novartis.
We have this wonderful molecule, 6160. We used it a lot to understand what VAV1 actually does and where degrading it will work best. Turns out, it's really important in chronic signaling in autoimmune disease between T and B cells. And so it opened up a lot of future development opportunity in any autoimmune disease that's either T cell-driven or T cell, B cell-driven. And obviously, with the 2 trials that are now disclosed from Novartis, that's exactly sort of that type of biology.
Great. And in terms of Novartis' initial indication choices, why do you think they prioritized Sjogren's and PsA? And what are some other indications that you think make sense?
Yes. So as just anything that's T cell or T cell-mediated, preclinically, for those who have looked at our corporate decks in the past, we've worked in IBD, could make a ton of sense to work there. We did a rheumatoid arthritis model. In general, anything arthritis would be great indications and hence, probably the psoriatic arthritis trial, other things.
Novartis will not stop at those 2 trials, right? Our guidance is Novartis planning to start several additional trials. So I don't even think they've prioritized Sjogren's. So it was just, like, 'Here is, like, a range of indications. Let's just, like, go full steam ahead and whatever starts first, just, like,' starts first because it was the quickest path to initiating a trial.
So we're super excited. As you might know, we actually own 30% of the profit, also of the losses in the U.S. And so from a commercial value creation opportunity for us, still a huge product. It's not a simple license with future royalties. It's really a collaboration where we feel still that sense of ownership and obviously benefiting from the fact that for now, we don't have to pay anything until Phase III for development. So Novartis is essentially helping us to derisk some of these indications.
And at what point do you need to make that decision about the profit share?
So it's not an opt-in, right? I mean it's essentially an opt-out. So we're in until we decide it's too much. All that said, the 30% profit share doesn't mean we have to pay 30% of future development costs. We believe it's fairly manageable, but I'm sure if there was a need, we could always opt out and revert to a more conventional structure.
Okay. I'll pause here and see if there are any questions from the audience.
Okay. Would you like to spend the last few minutes then talking about your GSPT1 program?
Definitely. Sort of in general, I mean, sure, I mean, like VAV1 and NEK7 are massive, right? And then the oncology always seems like a little bit of a side gig. We really like sort of that setup of being able to work across multiple disease areas.
I think 2359, our GSPT1 degrader, has generated great data in prostate cancer. It's a small data set on just like for now 5 patients. We'll have an update coming that has actually 1 additional patient, but a great data set with like 100% PSA responses and like literally, each patient had a tumor shrinkage, 2 of them to the degree of a PR. I think this is an asset that over time can move into multiple different combination strategies in prostate cancer, which we like.
As you know, we also have a CDK2 and the Cyclin E1 degrader program that are now approaching IND. CDK2 will likely go first next year and then followed by Cyclin E1. And again, at a time where many of the CDK2 inhibitors out there are turning out to be not as selective as advertised and too toxic. And we think these will create great opportunities for us.
So, kind of, coming back to, sort of, the beginning and the pitch of molecular glue degraders, I think what we have learned over the last 7 years is that not only can we go after completely undruggable things, we can make these degraders also exquisitely selective, right, like, our CDK2 degrader degrades CDK2 and nothing else, like no other kinase, no other protein. And I know because I can measure that on a cellular level in proteomics.
This isn't like a biochemical like assay array of like 20 different kinases and I'm sort of guessing. We really know about our selectivity, and that's really created unbelievably cool safety packages at least preclinically, and whether we apply this in I&I or in oncology doesn't really matter.
Great. Well, I think we can leave it there. Thank you so much for being here with us, and thank you, everyone, for joining.
Super. Thanks for the invite.
Monte Rosa Therapeutics Inc — Special Call - Monte Rosa Therapeutics, Inc.
1. Management Discussion
Greetings, and welcome to the Monte Rosa Therapeutics conference call to discuss the company's clinical results from the GFORCE-1 Phase I study of MRT-8102. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Andrew Funderburk, Chief Investor Relations and Strategy Officer at Monte Rosa. Andrew, you may begin.
Good morning, and thank you for joining us to discuss results from GFORCE-1, a Phase I study of MRT-8102, our NEK7-directed molecular glue degrader in subjects with elevated cardiovascular disease risk. Joining me today are Markus Warmuth, Chief Executive Officer; Filip Janku, Chief Medical Officer; and Manav Korpal, Senior Vice President, Translational Research.
Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please refer to our annual report and other filings we make with the SEC for our risk factors and other information. We issued a press release this morning summarizing today's clinical data update. A copy of today's presentation is available in the Events and Presentations section of our IR website. With that, I will turn the call over to Markus.
Thank you, Andrew, and good morning, everyone. Today, we are delighted to report the full results from our GFORCE-1 study, the part three of our Phase I first-in-human study for our NEK7 molecular glue degrader MRT-8102. GFORCE-1 follows on the heels of remarkable and benchmark setting data from our single ascending dose and multiple ascending dose or SAD/MAD portion of the trial. As a reminder, we reported data for the earlier portion of the trial in January this year, and that data as well as information on the entirety of our pipeline can be found on our corporate website.
Let's turn back to today's update on MRT-8102. MRT-8102 is a molecular glue degrader of NEK7. And we have shown before in preclinical models that depleting NEK7 leads to a substantial and sustained block of the assembly of the NLRP3 inflammasome referred to in today's update as the NEK7/ NLRP3 complex. Our GFORCE-1 human data confirmed now that MRT-8102 does exactly what we designed to do. It degrades NEK7 potently, it reduces an array of key molecular drivers of plot progression and vessel wall remodeling that are fundamental in atherosclerotic cardiovascular disease, or ASCVD, a complicated and multifaceted disease, and it does so with a favorable safety and tolerability profile. We believe that the positive results reported today validate the power of our approach and strongly support continued development of MRT-8102 across multiple indications, including the three indications we will focus on today, ASCVD in particular, coronary artery disease or CAD; hidradenitis suppurativa or HS; and gout.
GFORCE-1 enrolled 108 subjects with elevated cardiovascular risk randomized to MRT-8102 at 5, 20 or 40 milligrams once daily over to placebo for 4 weeks of dosing followed by 4 weeks of safety follow-up. On safety, consistent with the data we previously reported with MRT-8102, the overall safety profile observed was highly favorable. There were no serious adverse events and the treatment emergent adverse event rate, predominantly grade 1 events was comparable to placebo at 33% versus 30%. Importantly, we saw no evidence of increased infection risk. On target engagement, we saw robust and sustained NEK7 degradation of approximately 80% to 90% in line with what we had seen in the SAD/MAD portion of the Phase I trial and degradation was comparable across all three dose levels. Importantly, pathogenic drivers of ASCVD, including those indicative of atherogenic and thrombogenic risk like various DAMPs and IL-1 beta as well as systemic inflammatory markers were reduced to levels comparable with healthy volunteers at every dose level tested.
Finally, we saw an important precision medicine signal that could be helpful for efficient future development. Carriers of NLRP3 risk alleles had higher baseline DAMP and IL-1 beta levels, which identifies a genetically defined population that potentially carries higher risk of progression and that we will consider enriching for in our development program. We do believe and will show you data that many, if not all the pathogenic drivers measured in GFORCE-1, so in a CBD context, will be relevant in other indications as well, turning our GFORCE-1 results into a broadly valuable translational data package. Taken together, our clinical data, including the safety profile across all dose levels and the wide therapeutic margin support broad development of MRT-8102 across multiple NEK7/NLRP3-driven diseases.
Now let's spend a few minutes to go deeper into the rationale and the disease biology and why we chose to target NEK7. As seen on Slide 5, multiple intrinsic and genetic factors can promote NEK7-mediated assembly of the NEK7/NLRP3 complex. NEK7/NLRP3 activation triggers pyroptosis and the release of inflammatory cytokines, such as IL-1 beta and IL-18, DAMPs, such as HMGB1 and calprotectin and other disease-promoting factors. Cytokines drive multiple downstream inflammatory pathways while DAMPs further amplify NEK7/NLRP3 activation, creating a self-sustaining cycle of pathway activation that if left unchecked promotes tissue injury and remodeling.
The feed forward biology is a key driver of pathology across NEK7/NLRP3 mediated diseases, but in particular, in ASCVD, gout and HS can be referred to this broad cascade of events as the NEK7/NLRP3 pathway or signaling cascade. Because NEK7/NLRP3 complex sits upstream of these pathogenic processes, we believe the targeted degradation of NEK7 may deliver meaningful therapeutic benefit across the already mentioned and additional NEK7/NLRP3 indications.
Moving to Slide 6. We have mentioned our excitement of pursuing clinical development in ASCVD, gout and HS, so let's walk through where this excitement is coming from. This slide summarizes our internal analysis of publicly available disease-centric data sets asking which diseases show the most NEK7/NLRP3 activation. To do this, we performed an unbiased enrichment analysis across hundreds of diseases using an in-house curated NEK7/NLRP3 activation signature. ASCVD, gout and HS emerged among the higher scoring indications. Importantly, diving deeper into the data now on a single gene level, all three indications showed consistent upregulation of NLRP3 itself and of associated downstream cytokines and DAMPs in disease tissue relative to healthy tissue. We believe this consistent elevation of both NLRP3 itself and its downstream pathogenic mediator suggest that the pathological consequences of NEK7/NLRP3 activation are conserved across indications, spanning various organ and tissue types, and support the learnings from one indication and in particular, from our GFORCE-1 data can be extrapolated to other indications in the future. Collectively, we believe these data support the relevance of NEK7/NLRP3 signaling in these indications and our prioritization for future development of MRT-8102.
Moving to Slide 8. Let's now focus on the rationale for and our excitement around ASCVD and CAD in particular, and why we think targeting NEK7 will be superior to any other approach in the pathway. We believe the conventional view of the NEK7/NLRP3 pathway has been oversimplified, overlooking the complex biology it drives within atherosclerotic plaques. As shown on this Slide 8, NEK7/NLRP3 and its downstream effectors affect multiple aspects of plaque biology, influencing multiple cell types and processes that collectively drive atherosclerosis and atherothrombosis. NEK7/NLRP3 activation in plaque resident monocytes and macrophages drives the release of IL-1 beta, IL-18, DAMPs, and prothrombotic mediators that collectively promote endothelial cell dysfunction, oxidized LDL retention and foam cell formation, smooth muscle cell remodeling, vessel wall alterations and thrombosis.
Together, these changes accelerate plaque growth, instability and after thrombosis eventually raising the risk of cardiovascular events. We believe only upstream targeting of the pathway, for example, through NEK7 degradation and NEK7/NLRP3 disassembly, we'll be able to control this complex biology to a point where therapeutic benefit can be derived. So in the following few slides, allow me to provide clinical and scientific evidence for what we just explained. We will show you how colchicine, a drug that blocks NLRP3 signaling by acting on the NLRP3 complex, has shown positive clinical outcomes as opposed to recent results with an IL-6 antibody that acts further downstream. Interestingly, colchicine has been shown to block NLRP3 complex formation, so act similar to MRT-8102, albeit by a quite different mechanism: it blocks the function of cytoskeletal components important for this process and hence, has a much narrower therapeutic margin. We will also show human genetic data demonstrating the superiority of upstream targeting. And lastly, we will provide you our analysis of ASCVD risk factors, again showing that the upregulation of many upstream ASCVD pathogenic drivers carries more significance than downstream markers like IL-6.
Slide 9 shows a summary of important clinical trials completed in this space. We believe the results of these trials support targeting the upstream nodes of the NEK7/NLRP3 pathway in general and of NEK7 in particular. So for example, as opposed to ziltivekimab, an antibody to IL-6 that targets the downstream acute phase response and that fail to reduce MACE compared to placebo in a clinical trial called ZEUS. Colchicine led to significant MACE reductions in two trials, LoDoCo2 and COLCOT trials. Both trials had focused on patients with stable CAD post-myocardial infraction. Not shown on this slide, in addition to these trials, colchicine was also tested in a more acute setting within 72 hours of a myocardial infarction in the CLEAR SYNERGY trial. Although CLEAR SYNERGY was ultimately neutral, patients enrolled before the COVID-19 pandemic and those on the original twice-daily colchicine regimen showed MACE reduction. The trial was then substantially affected by the COVID-19 pandemic, leading to disrupted dosing schedules, underreported events and access non-cardiovascular deaths as well as a protocol amendment that lowered the colchicine dose.
Beyond these landmark trials, we believe broader clinical evidence, including several matter analysis of patients treated with colchicine further reinforce the importance of upstream targeting of the NLRP3 pathway. [indiscernible] which is no increased infection risk was seen in treated patients. While colchicine is approved to reduce MACE in patients with established atherosclerotic disease and patients with multiple risk factors for cardiovascular disease, it is only partly prescribed due to its significant GI and other side effects. In addition to colchicine, canakinumab and IL-1 beta targeting antibody also led to positive MACE effects with a hazard ratio of 0.85. However, due to the broader role of IL-1 beta across multiple inflammasomes and in other immune pathways, the drug showed an increased rate of severe and lethal infections and we understand that, that was the reason why the drug did not make it to an approval.
Human genetic data are also very supportive of the NEK7/NLRP3 complex as a target for upstream ASCVD. Indeed, there are two known activating SNPs in NLRP3 that have been studied extensively. The graph on the left of Slide 10 shows that the NLRP3 TT risk allele variants that activate the NEK7/NLRP3 signaling cascade are associated with the 1.6 to 2.3-fold higher odds of CAD across independent cohorts. By contrast, an established IL-6 receptor protective allele is only a very modest protective benefit in all comers. The hazard ratio for that for that protective allele, while statistically significant is 0.97 and it required analysis of hundreds of thousands of patients to gain certainty about its impact. A benefit for the IL-6 receptor allele is only obvious in the small subset of CHIP associations with clonal hematopoiesis of indeterminate potential, a condition that directly drives IL-6 expression. As shown on the right, NLRP3 risk on new carriers also show a markedly elevated NLRP3 dependent expression of key pathogenic drivers of ASCVD, including for IL-1 beta. Something we have also looked at in GFORCE-1 as you will see soon.
Finally, as shown on Slide 11, many upstream pathogenic ACV drivers, including DAMPs like calprotectin, S100A12, and the thrombogenic factor SAA and cytokines like IL-1 beta are not just upregulated in human atherosclerotic clots in general, they are even more upregulated in unstable atherosclerotic clots, so it's no surprise, and this is what is shown on the right, that all these key ASCVD pathogenic drivers are independently associated with higher CV risk and they appear to be linked to significantly higher risk than IL-6 or LP(a) as a comparison. Taken together, we believe that the human genetic association of NLRP3 risk alleles with CVD, the past clinical trial results with colchicine and canakinumab and the dominant role of IL-1 beta and DAMPs and plaque in vessel biology and as independent CVD risk factors provide strong support for targeting the NEK7/NLRP3 pathway as far upstream as possible.
At points in the cascade where intervention has the potential to modulate a broader network of pathogenic drivers and cellular processes contributing to plaque initiation, progression and instability. Furthermore, we believe that NEK7 is the optimal target for such upstream intervention.
With that, I will hand it over to Filip and then Manav to describe how our GFORCE-1 data further support and validate our hypothesis. Filip will start by walking you through the study design and pharmacodynamic and safety results. Manav will then present data from our unique transitional approach with a focus on determining MRT-8102's impact on key molecular drivers of atherosclerotic plaque formation, progression, instability and rupture including many of the DAMPs mentioned before as well as IL-1 beta.
Thank you, Markus. Slide 13 outlines the GFORCE-1 study design. As Markus mentioned, given the promising activity and safety data we generated for MRT-8102 in our SAD/MAD study, which we disclosed earlier this year, we advanced MRT-8102 into a randomized double-blinded placebo-controlled dose exploration study to obtain additional activity data while also enrolling subjects with increased risk for developing atherosclerotic cardiovascular disease. To this end, our GFORCE-1 study was designed to enroll obese participants with elevated CRP levels ranging from 3 to 50 milligrams per liter, placing them at increased risk for developing atherosclerotic cardiovascular disease.
Participants were randomized to receive 5, 20 or 40 milligrams of MRT-8102 or placebo once daily for 28 days, followed by a 28-day safety follow-up. Primary endpoints included safety and tolerability, while secondary endpoints included changes in pharmacokinetics and hsCRP. Exploratory endpoints assessed NEK7 expression levels, inflammatory and atherogenic DAMPs, cytokines, lipids, lipoproteins and other pathogenic factors relevant to the development of atherosclerosis.
Slide 14 details baseline characteristics of our study participants, which were generally well balanced across the treatment groups. Participants had a median age of 41 years, so approximately 20 to 30 years younger compared to a typical, fully established ASCVD population. And the median BMI of approximately 34 kilograms per square meter with elevated hsCRP consistent with an inflammatory cardiovascular risk population. Importantly, there were no meaningful baseline differences across groups that would be expected to impact interpretation of the study results.
Turning to Slide 15. MRT-8102 demonstrated robust degradation of NEK7 across all three dose levels tested, this 80% to 90% degradation noted in peripheral blood T cells and no apparent dose dependency. The level of degradation in GFORCE-1 was comparable to the marked degradation noted after both single and multiple administrations in the SAD/MAD healthy volunteers portion of the study. In summary, these data demonstrated rapid, robust and sustained degradation with continued dosing of up to 4 weeks.
Turning now to our study results. We will begin with a review of our unblinded safety data, which we are happy to report demonstrated favorable safety profile. Slide 16 details unblinded safety data for participants enrolled in GFORCE-1. Safety data were collected over 8 weeks for 108 participants, of which 81 were treated with MRT-8102 across three dose levels, and 27 were treated with placebo. No serious adverse events were reported. Treatment-emergent adverse event rates, which reflect any AEs on treatment regardless of attribution to drug, they were similar between MRT-8102 and placebo with rates of 33% and 30%, respectively. 86% of events were grade 1, with the most common events being headaches and otalgia, both occurring at similar rates between MRT-8102 and placebo. As we previously disclosed, there was one episode of grade 3 elevation of liver enzymes in a participant with an incidental finding of asymptomatic hepatitis A. There was also one episode of grade 3 shoulder pain in a patient with accidental shoulder dislocation. No serious infections were reported and overall infection rates were similar at 7% in both groups.
In summary, overall safety over 8 weeks was comparable to placebo across the dose range evaluated. Slide 17 provides safety data in more detail. Over 4 weeks of dosing, followed by 4 weeks of additional safety observation for a total of 8 weeks. MRT-8102 was generally well tolerated with no serious adverse events. No adverse events of neutropenia or thrombocytopenia were observed across any dose group. In addition, to the above-referenced hepatitis A case in the 40-milligram cohort, there were seven other treatment discontinuations, four in the 40-milligram cohort and three in the 20-milligram cohort, mostly related to grade 1 events. Importantly, and as mentioned, infection rates were balanced across all groups, including placebo, with no serious infections reported. Overall, these data support a favorable safety profile and establish a wide, safe dose range to move forward with our three prioritized indications. As we will discuss in a few minutes when we review our Phase II development plans, we will use the now defined safe dose range of 5 to 40-milligram to determine an optimal dose range for each indication.
I'll now hand the call over to Manav to review our data on the clinical activity of MRT-8102 and pathogenic drivers of ASCVD. Manav?
Thank you, Filip. Before we take a deep dive into the clinical activity analysis, it's important to understand the GFORCE-1 population as detailed on Slide 19. These were subjects with obesity and elevated cardiovascular risk but without a requirement for established ASCVD. Interestingly, a large prospective study published this year by Bundgaard and colleagues suggests that up to 70% of asymptomatic adults aged 40 to 49, which is comparable to the median age of our GFORCE-1 cohorts, had detectable atherosclerosis. This study, coupled with another published by Yang and colleagues in 2013, highlighting that CRP and BMI independently associated with vascular inflammation strongly suggests our GFORCE-1 population is likely enriched for participants bearing vascular inflammation and or plaque burden.
Consistent with this, the baseline profile of our GFORCE-1 subjects showed the expected elevations in ASCVD associated drivers and broadly tracked with patterns reported in established ASCVD. Although the magnitude of elevation may not necessarily be equivalent. We used the healthy volunteer cohort from the SAD/MAD portion of our trial as a real world reference for normal physiological levels of local pathogenic drivers of ASCVD and systemic biomarkers, and we explored whether human genetic features, in particular, activating SNPs and NLRP3 led to higher baseline levels in key pathogenic ASCVD drivers in our GFORCE-1 cohort.
With that context in mind, I'll now walk you through the framework we use to interrogate key pathogenic drivers contributing to ASCVD. As shown in Slide 20, directly downstream of NEK7/NLRP3 activation, we looked at proximal markers that might inform on atherogenic and vascular processes, including IL-1 beta, DAMPs and thrombogenic factors. These markers can inform on vascular remodeling status, and they have well-characterized roles across multiple aspects of plaque biology, including plaque initiation, progression, destabilization and thrombosis. Further downstream, we assess IL-6 and CRP, which reflect the systemic acute phase response. So overall, this framework allows us to examine the entirety of the pathological cascade from proximal plaque and vascular biology to the downstream systemic response.
Now let's turn to data from our study. Slide 21 shows the baseline levels of the aforementioned proximal and a few distal or systemic markers in our GFORCE-1 population compared to what we saw in our healthy volunteer reference population. In brief, and importantly, we see coordinated elevation across the above delineated cascade of both proximal and distal ASCVD drivers and markers. So even without confirmed ASCVD, as mentioned, it appears the pathogenic biology relevant to cardiovascular disease is engaged in a subset of subjects that reinforces the strength of our study designs.
Moving to Slide 22. Having seen elevated baseline levels of various ASCVD relevant drivers we want to take things a little further, and we next look at whether the NLRP3 risk alleles that Markus had referenced during his intro are associated with those elevations. As discussed, and NLRP3 gain of function SNPs are significantly associated with higher odds of coronary artery disease as supported by multiple independent data sets. These moderate to high-risk genotypes are not uncommon. In fact, our analysis shows that activating NLRP3 SNPs are highly prevalent in the GFORCE-1 population. Nearly 1 in 3 subjects carried the highest risk genotype and more than half carried a moderate risk genotype.
Importantly, in GFORCE-1, the underlying genetics were compellingly associated with higher levels of DAMPs, IL-1 beta and acute phase response proteins at baseline extending literature findings to DAMPs. This provides evidence of increased pathway activity in NLRP3 risk gene carriers and support the potential use of NLRP3 genetic profiling to enrich for patients more likely to bear NLRP3-driven CV risk.
Now let's discuss the impact of MRT-8102 treatment on proximal pathogenic markers, like DAMPs and IL-1 beta. All known to play a significant role in plaque and vascular biology and atherogenic progression.
Slide 24 dives deeper into the biology of DAMPs, pathogenic drivers that have long been underestimated in their significance in ASCVD. Indeed, a substantial body of evidence indicates that DAMPs function as potent amplifiers of inflammation across various diseases creating a feed forward loop that reinforces NEK7/NLRP3 activation and propagates pathogenic signaling. They also, as shown before, tend to be more meaningful ASCVD risk factors than downstream cytokines like IL-6. As an example, calprotectin is a well-studied DAMP implicated in ASCVD. As we discussed, calprotectin is significantly enriched in unstable plaque and is independently associated with increased cardiovascular risk. Consistent with this, and as shown on the right side, circulating calprotectin levels correlate with greater plaque burden while plaque calprotectin expression is enriched in atherosclerotic lesions and closely associated with features of plaque instability. Similar data also exists for other DAMPs that are released by NEK7/NLRP3 trigger keratosis.
Moving to Slide 25. In cell-based assays, we functionally confirmed MRT-8102 potently inhibits pyroptosis and hence, release of IL-1 beta and multiple DAMPs, including calprotectin. By contrast, IL-1 and IL-6 biologics fail to inhibit pyroptosis, do not block the release of DAMPs and only neutralize IL-1 or IL-6, respectively. This is a critical mechanistic distinction that functionally supports the therapeutic potential of upstream targeting in this crucial signaling cascade.
Let's now turn to the clinical data demonstrating these effects in humans. Slide 26 shows our data on how treatment with MRT-8102 affects levels of calprotectin. At baseline, calprotectin levels were elevated versus healthy volunteers, as shown on the left. Following treatment with MRT-8102, calprotectin declined rapidly with a market reduction by week 4, moving down to levels equivalent to what was measured in healthy volunteers. This analysis is across the three treatment cohorts grouped together.
Breaking this out by dose level, Slide 27 illustrates consistent reduction in calprotectin across all three dose cohorts. At all doses, calprotectin was reduced by approximately 50% to 60% and with levels at week 4 returning to the range observed in healthy volunteers. This consistency across doses is also aligned with the NEK7 degradation profile shared earlier. Given the consistent activity across the dose levels in the next set of analyses for simplicity, we'll group all three dose levels together. Slide 28 presents an analysis for two additional pathogenically relevant DAMPs, S100A12 and SAA. Although the magnitude of elevation in GFORCE-1 was more modest as compared to calprotectin, we did observe a significant reduction in both after 4 weeks of dosing. As with calprotectin, these reductions brought levels back to those observed in healthy volunteers.
Now let's turn to two additional significant local ASCVD drivers, HMGB1 and IL-1 beta, both of which have been shown to work in concert to drive plaque formation, progression and rupture in ASCVD. As a matter of fact, if you remember the earlier analysis of ASCVD risk factors, these are the two highest ranking risk factors, and modulation of these will be key for successfully improving MACE outcomes.
Slide 29 focuses on the role of HMGB1 and IL-1 beta and how they work together. After being released from monocytes and macrophages following NEK7/NLRP3 activation, HMGB1 acts across multiple plaque residue cell types, promoting endothelial cell activation and vascular smooth muscle cell remodeling. HMGB1 itself can further trigger NEK7/NLRP3 dependent IL-1 beta production and vice versa, IL-1 beta itself can further amplify HMGB1 release and contribute to local inflammation and matrix remodeling. Consistent with this biological crosstalk, HMGB1 and IL-1 beta show a strong correlation at baseline in our GFORCE-1 population supporting coordinated modulation of this proximal disease driving access.
Moving on to Slide 30. We now take a look into whether both HMGB1 and IL-1 beta are elevated in our GFORCE-1 population and are similarly impacted by MRT-8102 treatment. Indeed, as shown on the left, HMGB1 was elevated at baseline in at least a subset of GFORCE-1 subjects relative to healthy volunteers, although not as dramatically as calprotectin. Importantly, among participants with baseline HMGB1 levels above 4.7 nanograms per milliliter, representing the upper quartile in the study population, MRT-8102 treatment reduced HMGB1 levels by 40% by week 4, bringing levels closer to those observed in healthy volunteers and to the median of the group.
We next examined endogenous baseline and treatment-induced levels of a highly inflammatory cytokine IL-1 beta as shown on the right. Importantly, these data reflect endogenous circulating plasma levels of IL-1 beta, so they're not derived from artificial ex vivo stimulation experiments as typically shown by others. Also keep in mind that circulating levels of IL-1 beta are usually difficult to detect as IL-1 beta is mostly tissue resident, so we applied a high sensitivity assay to reliably quantify the extremely low levels that are circulating in plasma. In healthy volunteers, IL-1 beta values cluster tightly, which is expected for a cytokine this potent and active. That said, a significant elevation of baseline IL-1 beta levels was observed in GFORCE-1 subjects, further confirming the enhanced inflammatory state of this cohort. Finally, similar to HMGB1 and those with upper quartile baseline levels, there was a significant treatment-induced reduction of 37% by week 4, bringing them closer to healthy volunteer levels.
Taken together with the data shown before, the overall pattern of down modulating DAMPs is consistent with selectively lowering elevated key pathogenic drivers of ASCVD toward physiological levels and validates NEK7 degradation by MRT-8102 as a potential path to controlling plaque and vessel wall resident pathological changes in ASCVD.
Building on the data for upstream drivers of plaque progression in ASCVD, we next turn to proximal thrombotic factors as shown on Slide 31. While tissue factor and fibronectin were not elevated at baseline, fibrinogen levels were clearly increased in GFORCE-1 subjects compared to healthy volunteers. Over 4 weeks of treatment with MRT-8102, median fibrinogen decreased by about 28%, returning to levels observed in healthy volunteers while placebo showed no meaningful change.
Having established consistent modulation of proximal NEK7/NLRP3 associated [ levers ], we next move downstream to markers of systemic inflammation and the acute phase response. While these markers are further removed from the NLRP3 complex and potentially not as significant in driving ASCVD, they do provide an important readout of whether proximal pathway modulation translates into broader systemic effects. To this end, we assess the baseline and therapy-induced changes in the IL-6 CRP access.
As shown on Slide 33, MRT-8102 produced a rapid and sustained reduction in CRP across all dose levels, normalizing from elevated GFORCE-1 baseline towards healthy volunteer levels. Notably, 88% of subjects achieved reductions of CRP to below 2 milligrams per liter, a threshold associated with lower cardiovascular risk as defined by the CANTOS trial. As expected, IL-6, the cytokine that induces release of CRP from the liver showed a similar normalization to a lower risk healthy volunteer range.
In summary, NEK7 degradation and inhibition of the NEK7/NLRP3 signaling cascade appears to translate meaningfully into reduction of systemic inflammation. Collectively then, the comprehensive analysis we shared today demonstrates that MRT-8102 can optimally reduce pathologic levels of multiple drivers that are relevant to plaque formation, progression and rupture as well as vessel wall remodeling back to normal physiological levels that are equivalent to the levels we found in our healthy volunteer population.
Based on these findings, we're very excited about the opportunities presented by MRT-8102. With that, I'll turn the call back to Filip to provide an update on our clinical development plans for MRT-8102. Filip?
Thank you, Manav. Slide 35 discusses our differentiated approach to a Phase II study of MRT-8102 in CAD, a subset of ASCVD. Our goal is to inform an innovative and efficient design of a future Phase III study focused on a patient population in [ this liable ] disease and the highest need for intervention. We plan to build on the learnings from prior anti-inflammatory cardiovascular trials that showed MACE benefit in stable CAD populations, supporting intervention during the chronic phase when residual inflammatory risk persists.
While we continue to refine our dose exploration and build our safety data set in a chronic disease setting, we will use GFORCE-2 to optimize our strategy for imaging, biomarker and genetics-based enrichment of high-risk patients with potential for more significant MACE benefit in a future Phase III trial. We will use coronary artery imaging, including fat attenuation index or FAI as a means of assessing plaque inflammation at baseline and during the course of treatment. We will evaluate the modulation of upstream pathogenic drivers of atherosclerosis and thrombosis, including DAMPs, cytokines and thrombogenic factors. Finally, we'll confirm the impact of NLRP3 risk alleles for NEK7/NLRP3 pathway activation, the impact on baseline of regulation of pathogenic drivers of ASCVD, responsive dose to MRT-8102 and any FAI changes.
Slide 36 lays out the trial schematic. GFORCE-2 is a Phase IIb study in approximately 160 patients with stable coronary artery disease and residual inflammation. Patients will be randomized across three MRP-8102 dose levels, 5 milligram, 10-milligram and 15-milligram or placebo and treated for 6 months. The study is designed to provide proof of concept by assessing changes in plaque biology through cardiac imaging and investigating changes to levels of key molecular drivers of ASCVD as well as systemic biomarkers, thrombogenic factors and lipids and lipoproteins. We will also confirm frequency of the NLRP3 moderate and high-risk genotypes, along with pharmacogenomic correlations, liver inflammation and any impact on anemia. We believe the 6-month treatment period will be important to fully evaluate imaging and analysis of plaque inflammation through FAI. With these extensive changes from our original design, study initiation is now planned for the first half of 2027.
Now I'd like to briefly discuss two additional Phase II studies we are planning for MRP-8102 shown on Slide 37. Our GEMINI-1 study will seek to establish proof-of-concept for the prevention of flare recurrence after management of an acute gout flare with study initiation expected in Q4 2026 or Q1 2027 with a data update expected in the second half of 2027. We expect to enroll around 60 patients with recurrent gout flare with end points, including reduction in pain score at 72 hours and frequency of new flares over 12 weeks of treatment. Our Phase II GALAXY-1 study, detailed on the right, will evaluate efficacy and safety in moderate to severe HS. We plan to enroll around 160 patients randomized to MRT-8102 or placebo, with the primary efficacy outcome being HiSCR75 after 16 weeks of treatment. Trial initiation is expected in the first half of 2027.
I'll now hand the call back to Markus to wrap up.
Thank you, Filip. Let's now turn to the big picture on the CAD opportunity. As shown on Slide 39, CAD remains a very large market with around 14 million patients in the U.S. Current ASCVD therapies address important individual drivers of disease but substantial residual inflammatory and thrombotic risk remains. Even patients who reach LDL targets can continue to experience cardiovascular events in part because chronic NEK7/NLRP3 driven inflammation and plaque is not adequately addressed.
The recent very large study showed that patients with plaque inflammation measured by FAI scores have strikingly up to nearly 30x greater risk of cardiac mortality. MRT-8102 is designed to target this NLRP3-mediated inflammatory risk with an oral therapy that could offer a favorable safety and tolerability profile and fit naturally alongside current standard of care treatments.
Slide 40 highlights the compelling opportunities presented by the three indications we're pursuing with MRT-8102. Looking beyond the CAD opportunity I just spoke about, we see a large opportunity in gout and in HS. Gout is a canonical NEK7/NLRP3 pathway disease. As is well documented in literature, MSU crystals trigger NEK7-mediated, NLRP3 assembly, driving IL-1 beta release and flare pathology. Breakthrough flares are common in gout patients despite standard of care therapy and flare prophylaxis is a major unmet need. It's notable that in a large physician survey, we conduct an over 55% of gout treating physicians indicated they were unsatisfied with current prophylaxis options.
Turning to HS. HS has the highest NLRP3 pathway activity scores of any indication we studied with consistent upregulation of NLRP3, IL-1 beta and DAMPs and lesional tissue. A large portion of patients are poorly managed with standard of care, and IL-1 antibodies provide a promising proof of concept for this approach in HS. Remarkably to date, no targeted oral immunomodulatory therapy has been approved for HS. We believe our NEK7 directed molecular glue degrader approach, has the potential to deliver a differentiated therapy for each of these indications and that the data presented today compels the continued development of MRT-8102 across CAD, gout and HS.
Moving to Slide 41. We believe that the remarkable data from GFORCE-1, especially the impact we are seeing on proximal disease drivers, including TAMs and IL-1 beta, validate NEK7 degradation using MRT-8102 as a differentiated broadly applicable approach to NEK7/NLRP3 driven diseases. The study demonstrated a favorable safety profile across all doses with no SAEs and no infection signal. We achieved robust sustained degradation of NEK7 at all dose levels. We saw broad clinical activity on local pathogenic drivers of ASCVD as well as systemic inflammatory biomarkers with all these reduced to healthy volunteer levels at all dose levels tested.
Finally, we identified patients carrying NLRP3 risk alleles as a potential genetically enrichable population with the further potential to correlate it with imaging-based plaque inflammation and morphology in future studies. We look forward to the launch of multiple Phase II studies to explore the potential of MRT-8102 in NEK7 and NLRP3-driven diseases, starting with our GEMINI-1 gout study initiating in Q4 this year or Q1 next year, followed shortly after by our GFORCE-2 CAD study and GALAXY-1 HS study in the first half of 2027. Moreover, our next-generation NEK7 degrader MRT-9347 will enter a first in-human study later this year.
Finally, on Slide 42, I'll have just a few additional highlights on the rest of our pipeline. We were pleased to see our collaborator Novartis activate two large Phase IIb studies for our VAV1-directed MGD, MRT-6160. Both the study in Sjögren's disease and the psoriatic arthritis study are now enrolling patients. We look forward to additional Phase II initiations to continue to broadly explore the potential of MRT-6160, across multiple immune-mediated diseases.
For our GSPT1 directed MGD, MRT-2359, we plan to present an update on our Phase I study in castration-resistant prostate cancer where we combine MRT-2359 with enzalutamide later this year. The confirmatory Phase II study of MRT-2359 in combination with apalutamide in ER mutant castration-resistant prostate cancer is now also actively enrolling, and we look forward to providing a clinical update in 2027. We also expect IND submissions for our CDK2 and cyclin E1 directed MGDs in 2027. In summary, with now three programs currently in or quickly approaching Phase II studies and multiple additional assets moving through IND-enabling studies, there has never been a more exciting time for Monte Rosa.
With that, I'll open the call for questions. Operator?
[Operator Instructions] Our first question comes from the line of Edward Tenthoff with Piper Sandler.
2. Question Answer
And I just blown away by the thoroughness of this data update and all the different markers and information it provided, really incredibly thorough, incredibly helpful. My question has to do with GFORCE-2 and the Phase IIb study. Appreciating that the outcome markers are going to be both imaging and pathogenic ASCVD drivers. Ultimately, I would anticipate this might require a cardiovascular outcome study. How is that data going to strengthen your understanding of what you might be able to show in terms of MACE or other outcome measures?
Thank you for that. Yes. So our plan, as you kind of correctly pointed out, is to use the GFORCE-2 to find the higher risk, but at the same time, modifiable subpopulations which then can be actually tested in the subsequent outcome study because in the Phase IIb with the 6 months administration, it's unlikely even in the population of patients with coronary artery disease, it's unlikely actually to see the outcome difference because the total number of the potential events actually will be quite low. But what we can do in the Phase IIb in GFORCE-2 is we actually can connect the plaque morphology through the imaging as the modulation of the critical disease drivers and how these relate to potential genetic features, as Markus just pointed out, particularly the SNPs in the NLRP3, the activating SNPs in the NLRP3. And that actually will ultimately allow us to have more efficient clinical trial design, the subsequent Phase III design, which will potentially -- which is expected to show the difference in outcome.
So you would potentially look for genetic drivers to -- or other factors to focus the population for a potential Phase III trial?
Potentially, yes. And I mean the expectation of the GFORCE-2 is that we will understand how these factors kind of all connect together and how they potentially relate to the local plaque biology, which as well as to some other markers associated with the [indiscernible] and systemic inflammation.
Our next question comes from the line of Michael Schmidt with Guggenheim.
I'm trying to better understand the predictability of the DAMP reductions that you sort of highlighted. And yes, maybe talk a bit more about how meaningful this sort of 50% reduction is. How strong is that sort of correlative data? Or is it just about normalizing levels of those DAMPs?.
Obviously, we view normalization as the way to go, I think, in previous meetings, we always emphasized it like taking a downstream cytokine out completely probably will lead to an infection risk because these cytokines are typically also important elsewhere, bringing local factors back to physiological levels in that context makes a ton of sense, right? Because you're now basically at the status of a healthy volunteer from a risk point of view. But obviously, the rest of your immune system in host defense can still appropriately respond. In particular, we're, of course, sure this would also go through some of the other inflammasomes.
Ultimately, of course, the next step here, as [indiscernible] has pointed out, is to now connect the normalization of DAMPs and IL-1 beta as a critical cytokine correlated to a plaque morphology and inflammation status by imaging. I think if we can build that connection, and then again, as Filip referred to connect both of the two genetic features, I think we should have a lot of evidence and, of course, also like a lot of confidence to move into an outcomes trial that hopefully would be run more efficiently which means fewer patients, faster and, of course far less cost.
And how do you interpret the IL-1 beta reduction seen in the GFORCE-1 study, perhaps in terms of translation to some of the more IL-1 beta-driven conditions like gout? And have you looked at IL-18 as well? Just curious.
Yes. Obviously, I'm super excited about those results. IL-1 beta, and we've pointed this out, Michael, in some of our previous conversations, super hard to measure in the blood. I think there's very few companies that present IL-1 beta blood data. We were fortunate to be able to establish an assay that's sensitive enough. If you looked at the Y axis, I mean, you're talking sample grams here, right? So these are low levels, IL-1 beta, just like HMGB1 tends to not go into the system. These are more tissue resident which will not be very different in gout and HS. And so seeing that and seeing that level of reduction we find super encouraging, hence obviously, super confident as we move into gout first and then together with GFORCE-2 also into HS.
And then just last question, just going back to the possible patient selection strategy in Phase III. I mean are you considering using genetic factors like an NLRP3, SNPs as a possible selection criterion or will it be more likely focused on specific clinical features?
Well, again, it depends, right? I mean obviously, if imaging, like perfectly correlates with NLRP3 SNPs, you would likely prefer imaging because that's a more established modality in ASCVD to characterize baseline inflammation. But I have to say, like the level of biomarker increase we're seeing here is very convincing. And so at the end of the day, the frequency of homozygous GGs already is 30%. And if you count in the [ GGs ], the ability to get over 50%, at the end, this becomes quite feasible even from a genetic selection point of view. Definitely, all the data we have for now suggest that there will be a population at higher risk, but still modifiable, and so it could, as I said, allow us to run a more efficient, smaller, faster Phase III trial at the end of the day.
Our next question comes from the line of Tyler Van Buren with TD Cowen.
This is Ikenna on for Tyler. It's great to see the updated, robust data. I had a question, what biomarkers or pathogenic drivers do you believe are most validated for predicting plaque progression? And which ones provide the strongest evidence that 8102 is affecting plaque biology rather than only the systemic inflammation? And I had a follow-up to that.
That's a bit the favorite child question. But I definitely think HMGB1 1, IL-1 beta as an access is absolutely crucial, I would go as far as if you're not modulating these two, it's going to be hard to see meaningful MACE activity. Obviously, we wish like the colchicine trials would have looked at these markets. Obviously, they didn't but like nice evidence obviously out there that even the lipid-lowering drugs like the statins, have an impact on HMGB1 expression, actually a quite significant impact. And so these are the two we will definitely look at.
I think, calprotectin obviously a little bit easier to measure, I think, would be another grade surrogate. At the end of the day, I mean, if you look at the aggregate data, and we didn't want to complicate things today with the heat maps and all sorts of fancy analysis, but on treatment, and these markets all start to correlate each other, right? So as you bring down HMGB1 and IL-1 beta, actually, your calprotectin also go down. Or maybe it's the other way around, we don't know. But the correlation at 4 weeks on treatment between those different DAMPs is really quite striking.
And for the other indications, HS and gout, are the same biomarkers relevant? Or are they different from ASCVD?
Definitely very, very similar, right? And we were trying to make the point in one of our intro slides. I mean if you look at existing data sets across these three indications, the pattern are strikingly different. I mean, if you would put that in front of me without a label for each of these diseases, I would have a hard time to assign the disease to the actual plots for those biomarkers. And so again, we really believe that what we're seeing in GFORCE-1 because of that similarity isn't just like sort of good data -- actually terrific data for ASCVD or CAD but also gives us a lot of guidance around gout and HS. And obviously, will really, really help us to also pick the appropriate doses per indication.
Our next question comes from the line of Derek Archila with Wells Fargo.
Congrats on the update. So just a couple of questions for us. So on the GEMINI-1 trial, I guess, this seems like this is going to be run without placebo, so what background rate of new flare should be assumed in the enrolled population?
Yes, Derek, it's a good question, this study will enroll patients with the acute flare and the incorporation of the placebo would not necessarily gain you much because like you have to allow the patients actually to use some rescue medications and like to a large extent, it's not really acceptable to have the patients with the acute flare to be on placebo. So in the reality, you wouldn't really have the placebo control, but you would have a very noisy rescue medications, which will be used in these patients. So I think from that standpoint, it doesn't really make much sense. The study also has a -- that's about acute flares, right? I mean the study also has another important goal, which is to look at what is the frequency of the flare recurrence during the 12 weeks of dosing. And in this one, I think you might make a case a little bit for placebo, but the expected effect size is actually quite large.
I mean, if you look at the historical data from a variety of trials, the frequency of the flares in this population, which will be the target population for the GEMINI-1, the expected flare rate is actually up to 60%. If you even find the most favorable data set, you will probably be somewhere in the 45% range while the expectation is that on the 8102, the expected flare rate will be actually much lower than that, so the effect size is actually quite sizable. So I think this trial actually is for the Phase II setting of the proof of concept appropriate.
And then on hidradenitis, I just want to get a better understanding on the translation here. Just for the doses that you're starting to evaluate, I guess, should we expect sufficient skin exposure to reproduce that direct IL-1 beta neutralization?
Yes, I think so. Yes, I think the data which we had from like a GFORCE-1, and subsequently, we will have them obviously from the GFORCE-2 as well. I mean, super relevant. I mean the MRT-8102 is a small molecule with the expected good penetration to the target issues. So actually, I think what we see now in the GFORCE-1 setting is very relevant to the other indications as well.
Our next question comes from the line of Faisal Khurshid with Jefferies.
Thank you so much for the really detailed presentation, felt like I was in grad school. I wanted to ask on the gout hypothesis, could you just explain to us how the NEK7 thesis compares to that of the URAT1 inhibitors? And I have another question as well.
Great question, actually. I love it because it is very complementary in regards to sort of the approaches, right? I mean, sure, URAT1 inhibitors will lower urate. Interestingly, this will likely still lead to quite a few flares, and it will be interesting to see how that actually impacts compliance with those drugs, right? But it's not a secret that urate-lowering drugs initially because they do mobilize urate and urate crystals have flares within at least the first 6 to 12 months. So long story short, we actually think that as an opportunity for us more than competition, right? As these hopefully come through in their clinical trials and hit the market, combining with something like 8102, great concept, right? Because then eventually, if you avoid flares in patients that are beginning to be on urate lowering drugs, you will definitely increase the compliance for both. So definitely, something on our radar as a potential development path on top of just the flare preventional approach in sort of the more regular, typical patient population.
And then I just wanted to ask for a clarification on the safety profile. I saw that 40 mg, it looks like you had three -- you said asymptomatic non-QVC grade 1 electrocardiogram changes. Can you just explain like what those were? And whether those are believed to be drug-related or not?
So we are not concerned by these findings at all, right? I mean, these changes were all grade 1 incidental and completely symptomatic, that's important to point out. These were kind of picked up on the regular frequent EKG so that -- which are done as a part of the Phase I study. And they were kind of associated with the change in the pattern of the T-a from the EKG and the -- so we've done appropriate workup and ruled out any ischemia or other organic heart pathology, which might potentially explain to them. So they are essentially changes which are not associated with any underlying organic cause which we can point out. It's also important to point out that we don't see any signals which will be related to QTc-related changes or anything like that. So overall, again, I would just explain that we are not concerned. And the -- looking at the overall totality on all AEs, the frequency of the AEs and MRT-8102 and placebo is nearly identical, it's 33% versus 30%.
Our next question comes from the line of Brian Cheng with JPMorgan.
This is Sarah on for Brian. The degradation of NEK7 and downstream impact, it really looks pretty similar across the 5, 20 and 40 milligram. What's driving dose selection for Phase II? So the pharmacodynamic profile seems largely saturated at the lowest dose. Can you expect a dose response that can be easily observable over the treatment course of 6 months in the GFORCE-2 trial? And then we have a follow-up after.
It's a great question. Obviously, we disclosed today that we're going to go forward with 5, 10 and 15 in GFORCE-2. We had a discussion whether we should go even lower. At the end of the day, obviously, we're trying to optimize GFORCE-2 for the maximum chance to see the correlation of imaging versus the plaque markets we're super interested in, and their genetics, and so we didn't really want to play around anymore with doses. In particular, in light of the safety that we're seeing here, I don't think you have many other molecules in this pathway that carve out such an impressive safety margin. So long story short, no, we're not expecting to see a dose response. But in the longer term setting, this will be 6 months, obviously, not 4 weeks. You never know until you eventually analyze the [indiscernible]
When you think about the other indications that are fundamentally different than heart disease, is there a need to treat the dosing just given the differences in tissues that you're aiming for? Especially like the diseases in gout and HS?
Another great question. Let me maybe start by just sort of making a point here that we really like this lineup of indications, right? I mean it's sort of proving the same pathway. And again, we made the point that the pathway overlaps very nicely, literally down to the actual disease drivers downstream that you want to measure, but they have different aspects, right, just like the chronic inflammation in ASCVD kind of a pure play NLRP3 or NEK7/NLRP3 signaling cascade disease. You have gout with an acute component, at least in that initial trial induced by crystals and then we sort of augmenting side of the pathway with HS, which gets to your actual question, yes, we are considering different dose levels. Part of it is sort of like getting into different organs. Part of it is also the acuteness of the disease.
I think you probably want to go higher in gout than you are starting in an acute situation, if you were in a preventative setting, so where you're just like trying to prevent future flares, maybe it could be lower. Again, really great that we have this very wide window now. I mean we're talking, just to keep it simple, roughly a 10-fold window and it could even be higher because, again, like who knows how we continue to be safe even above 40-milligram because there's a lot of opportunity to play around with a dose per indication and obviously, also in regards to the future commercialization and labels.
Our next question comes from the line of Oliver McCammon with LifeSci Capital.
Congrats on the data. Just given today's update, I'm curious in your level of confidence in an infection signal not emerging with 8102, particularly with longer dosing? And then separately, what would you need to see from GFORCE-2 in order to pursue a registrational strategy in ASCVD?
Confidence on infections is very high for two reasons, right? A, we believe that colchicine and the lack of an infection risk tells the story, right, like going after the NLRP3 pathway upstream sparing all other inflammasomes and other immune pathways really does the trick. I think what we have seen in regards through infection risk bias for both IL-1 beta and IL-6 really relates to just like taking these types of kinds out more or less completely where we at least have a broad function, not just in NEK7/NLRP3 signaling, and that sort of gets us back into the normalization versus wiping out message here, right, even if there was a residual rule for the NEK7/NLRP3 inflammasome in host defense by bringing things back to normal physiological levels rather than wiping out the downstream pathway altogether, we think there's definitely some level of response to infections left. So in a nutshell, at this point, very confident that we can avoid them.
And then just what you want to see from GFORCE-2 in order to pursue a future registrational strategy in ASCVD?
Yes. I mean, again, sure, I mean, we're aligning this up. Definitely, as you've seen a bit more complicated study than the average Phase II CVD study out there. The idea really is to see if we can use plaque imaging, the more relevant upstream pathogenic markers and potentially NLRP3 genetics to come up with a Phase III design that's more efficient in regards to a number of patients on length of the trial. And at the end of the day, of course, also magnitude of the MACE effect, which obviously are all intercorrelated, but that's really the goal of GFORCE-2. Again, we're very confident that GFORCE-2 will give us the information that we need, but we need to run the trial first, of course.
Our next question comes from the line of Robert Driscoll with Wedbush.
So just wanted to congrats on the comprehensive data here. So I wondered if you could talk more a little about the cardiac imaging endpoint for GFORCE-2 and what you might expect to see in this time frame? And then second question, just wondered if you'd look at how the level of NLRP3 pathway inhibition compares maybe preclinically to colchicine, just kind of given the clinical validation there.
I can take the preclinical question and the MRT-8102 actually is better inhibiting the pathway in our assays. Admittedly colchicine has a bit of a complicated molecule to handle in vitro. We are convinced that, I mean, if colchicine here leads the way, then we should at least be able to achieve equal results. Obviously, we'll be running those trials at a different point in time for sort of the overall cardiovascular health of a population. So you can see by our GFORCE-1 population on how there's still a lot of silent and known as an effect. But for us, it was silent ASCVD out there. Filip, do you want to address the imaging question?
Yes. The imaging is something which is really emerging over the last few years as something which is extremely promising, right? We already know and it has been, I would say, fully validated that the FAI index, which is actually quite easy to obtain because all you need is actually the CT, coronary imaging, I mean it has been historically done with using the technology with contact, but now it looks like that it can be done even on noncontact CT, which will actually make it even more simple and easy to do in the clinical practice routinely. But I mean we already know that actually the FAI index can be associated is really strong prognostic significance for the future MACE and cardiovascular mortality showing that the cardiovascular mortality, and we mentioned that during the presentation, can be actually increased 30-fold. So that's -- if you kind of put it to any other marker, which is out there, these numbers are pretty stunning.
What we also know it's a little bit more emerging evidence, but it has been also prospectively validated already, at least to some extent, although not in that massive number of patients as the prognostic significance. The FAI can actually change on therapies. If you have a therapy which targets atherosclerotic plaques and which modulates atherosclerotic plaques, you can see it in FAI in relatively short-term perspective, there are actually 15 weeks data out there. That was one of the reasons why we actually changed study duration from 3 months to 6 months because we believe that with the data which is out there from the prior prospective studies that the 6 months data is adequate time window where we can see the FAI changes.
Our next question comes from the line of Mitchell Kapoor with H.C. Wainwright.
This is [indiscernible], I'm sitting in for Mitchell Kapoor. Congratulations. So on Slide 17, it shows that you have no adverse event related to continuation of 5 milligrams versus three at 20 milligrams in five and 40 milligrams. Will you be able to characterize the asymptomatic non-PTC EPG changes and skin reactions and explain how those findings inform the planned Phase II dose trend?
Yes, absolutely. So I think one thing which I would point out we are not really concerned about it. There is one thing which is kind of important to understand that these were mostly grade 1 events. And in the therapeutic setting, these would be unlikely to lead to the treatment discontinuation, right? This was a population which was -- of participants in the cardiovascular risk, however, were volunteers not the patient. So the threshold for stopping the -- or discontinuing 8102 or therapy in general, was actually quite low. So I think I'm pretty confident that in the therapeutic trial when you have more motivated patient population, that vast majority, if not nearly all of these events would not actually lead to treatment discontinuation.
When it comes to these ECG events, I already commented on that. These were even which were asymptomatic, the appropriate work up did not identify any underlying organic cause which can explain them. So no organic pathology related to ischemia or anything else cardiac-wise. So what they exactly were associated with, there were some modulation in the T-a pattern. And again, I would like to emphasize that there were no QTc-related changes, which is obviously something -- which would be potentially a source of bigger concern. When it comes to the skin events, I mean we have seen a skin events in the study. They were present in both placebo and active drug overall, we didn't see in a significant or statistically significant difference between placebo and MRT-8102.
Thank you. And I'm currently showing no further questions at this time. This does conclude today's conference call. Thank you all for your participation. You may now disconnect.
Monte Rosa Therapeutics Inc — Special Call - Monte Rosa Therapeutics, Inc.
Financial data from Monte Rosa Therapeutics Inc
Revenue
Revenue is the sum of all sales generated by a company, e.g. for its products or services.
Revenue (TTM) metric explainedDirect Costs
Direct costs are the costs incurred directly in connection with the manufacture of the product or service.
Gross Profit
Gross Profit indicates how much of the revenue remains in the company after deducting direct production costs. If the percentage share of sales is calculated, this is referred to as the gross margin.
Gross Profit metric explainedSelling and Administrative Expenses
Selling, general and administrative expenses (SG&A) include all expenses for marketing and sales as well as the general administration of the company.
Research and Development Expense
Research and development costs (R&D) provide information on how much the company invests in the research and development of its products. The costs are particularly interesting as a percentage of revenue and in comparison to direct competitors.
EBITDA
EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is the company's earnings before interest, taxes, depreciation and amortization. The EBITDA margin is calculated as a percentage of sales.
Depreciation and Amortization
Depreciation represents reductions in the value of the company's assets (e.g. due to wear and tear on machinery).
EBIT (Operating Income)
EBIT (Earnings Before Interest and Taxes) is the company's profit before interest and taxes, also known as the operating income. The EBIT Margin is calculated as a percentage of sales at
.
Net Profit
Net Profit represents the profit or loss after deduction of all costs.
Net Profit metric explainedStocksGuide Premium
| Jun '26 |
+/-
%
|
||
| Revenue | 29 29 |
84%
84%
100%
|
|
| - Direct Costs | - - |
-
-
|
|
| Gross Profit | - - |
-
-
|
|
| - Selling and Administrative Expenses | 40 40 |
18%
18%
139%
|
|
| - Research and Development Expense | 171 171 |
32%
32%
594%
|
|
| EBITDA | -174 -174 |
846%
846%
-605%
|
|
| - Depreciation and Amortization | 8.13 8.13 |
3%
3%
28%
|
|
| EBIT (Operating Income) EBIT | -182 -182 |
1,316%
1,316%
-633%
|
|
| Net Profit | -161 -161 |
767%
767%
-561%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Monte Rosa Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Monte Rosa Therapeutics Inc Stock News
Company Profile
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.
StocksGuide Premium
| Head office | United States |
| CEO | Dr. Warmuth |
| Employees | 187 |
| Founded | 2019 |
| Website | www.monterosatx.com |


